Ischemic Neurological Interventional Medical Devices Market, by Device Type (Neurothrombectomy Device (Aspiration/Suction Catheters, Clot Retriever , Snare-like Devices, Others), Embolization Stents, and Stenting Systems), by Procedure Type (Mechanical Thrombectomy, Carotid Endarterectomy, and Stenting), by End User (Hospitals, Specialty Clinics, and Ambulatory Surgical Centers), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030

Published In : Nov 2022

Code : CMI5330

Pages :186

Formats :

Excel and PDF

Industry : Pharmaceutical

Market Challenges And Opportunities

Global ischemic neurological interventional medical devices Market- Drivers

The increasing focus on research and development by key players in order to strengthen their market presence in the global market is expected to drive growth of the global ischemic neurological interventional medical devices market over the forecast period. For instance, in October 2020, data was published by Centers for Disease Control and Prevention(CDC), according to which 1 in 6 deaths from cardiovascular disease were due to stroke. Every 40 seconds, someone in the United States has a stroke.

The increasing product launch and product approval by key players in order to strengthen their market presence in the global market is expected to drive growth of the global ischemic neurological interventional medical devices market over the forecast period. For instance, in September 2022, VESALIO, LLC., medical device company, announced the Conformitè Europëenne (CE) Mark approval for their new NeVa NET, micro-filtration technology coupled with NeVa’s Drop Zone technology creates a one-of-a-kind stent retriever, used to capture every type of clot and maximize the retention of clot for fast and effective recanalization of ischemic stroke.

Global ischemic neurological interventional medical devices Market: Restraint

As there are different trials going on for neurological interventional devices for ischemic stroke, there are more number of premature termination and withdrawal of clinical trials due to failure of not submitting the results within specific deadline, insufficient participation of subjects, device modification, protocol amendments, etc.

For instance, in January 2020, a clinical trial of Thrombectomy device called WOLF, used to remove thrombus, for ischemic stroke was withdrawn due to poor enrollment of subject in the clinical trial. The study was designed to evaluate the safety and device technical performance of the WOLF Thrombectomy Device in removing thrombus or as an adjunct to intravenous tissue plasminogen activator (TPA) and/or to other traditional, thrombectomy modalities.

Restraints & Challenges: